Evidence map›Paper›PMID 32242892›Full record

ArticleThe Biochemical journal2020

Interaction of the neutral amino acid transporter ASCT2 with basic amino acids.

Elias Ndaru, Rachel-Ann A Garibsingh, Laura Zielewicz, Avner Schlessinger, Christof Grewer

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Elias NdaruDepartment of Chemistry, Binghamton University, 4400 Vestal Pkwy East, Binghamton, NY 13902, U.S.A.
Rachel-Ann A GaribsinghDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, U.S.A.
Laura ZielewiczDepartment of Chemistry, Binghamton University, 4400 Vestal Pkwy East, Binghamton, NY 13902, U.S.A.
Avner SchlessingerDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, U.S.A.
Christof GrewerDepartment of Chemistry, Binghamton University, 4400 Vestal Pkwy East, Binghamton, NY 13902, U.S.A.
Binghamton University · USIcahn School of Medicine at Mount Sinai · US

Funding

TRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6M
Substrate Specificity Determinants in Nutrient Solute Carrier TransportersR01GM108911 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHLESSINGER, AVNER · 2014 to 2022
$3.1M
How to Combat Glutamate Release by Reverse Transport: Mechanistic Studies and Development of Selective Efflux InhibitorsR15GM135843 · NIGMS · STATE UNIVERSITY OF NY,BINGHAMTON · PI GREWER, CHRISTOF THEODOR · 2019 to 2019
$450k
NCI NIH HHS T32 CA078207NIGMS NIH HHS R01 GM108911NIGMS NIH HHS R15 GM135843
6 · The paper itself

Abstract

Glutamine transport across cell membranes is performed by a variety of transporters, including the alanine serine cysteine transporter 2 (ASCT2). The substrate-binding site of ASCT2 was proposed to be specific for small amino acids with neutral side chains, excluding basic substrates such as lysine. A series of competitive inhibitors of ASCT2 with low µM affinity were developed previously, on the basis of the 2,4-diaminobutyric acid (DAB) scaffold with a potential positive charge in the side chain. Therefore, we tested whether basic amino acids with side chains shorter than lysine can interact with the ASCT2 binding site. Molecular docking of L-1,3-diaminopropionic acid (L-DAP) and L-DAB suggested that these compounds bind to ASCT2. Consistent with this prediction, L-DAP and L-DAB, but not ornithine, lysine or D-DAP, elicited currents when applied to ASCT2-expressing cells. The currents were carried by anions and showed the hallmark properties of ASCT2 currents induced by transported substrates. The L-DAP response could be eliminated by a competitive ASCT2 inhibitor, suggesting that binding occurs at the substrate binding site. The KM for L-DAP was weakly voltage dependent. Furthermore, the pH dependence of the L-DAP response showed that the compound can bind in several protonation states. Together, these results suggest that the ASCT2 binding site is able to recognize L-amino acids with short, basic side chains, such as the L-DAP derivative β-N-methylamino-l-Alanine (BMAA), a well-studied neurotoxin. Our results expand the substrate specificity of ASCT2 to include amino acid substrates with positively charged side chains.

Indexed as

Amino Acids, BasicAmino Acid Transport System ASCAminobutyratesAnimalsBinding SitesEnzyme InhibitorsHEK293 CellsHumansKineticsMinor Histocompatibility AntigensMolecular Docking SimulationProtein BindingRatsSubstrate Specificity2,4-diaminobutyric acidAmino Acids, BasicAmino Acid Transport System ASCAminobutyratesEnzyme InhibitorsMinor Histocompatibility AntigensSLC1A5 protein, humanSlc1a5 protein, ratASCT2dockingelectrophysiologykineticsneutral amino acid transportersubstrate selectivity

Identifiers

PMID32242892
PMCPMC9535927
OpenAlexW3014501616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.